Hormonal acne guide: why it happens and what actually treats it

Hormonal acne is the term used for acne driven primarily by androgen-mediated sebaceous gland stimulation. It is extremely common — affecting the majority of adult women with persistent acne — and it has a distinct clinical pattern and treatment approach that differs from adolescent acne. Here's the complete picture.

What makes acne "hormonal"

All acne has a hormonal component — androgens stimulate sebaceous gland activity in everyone with acne-prone skin. "Hormonal acne" is the specific subset where androgen fluctuation is the primary driver, characterized by:

Adult onset or persistence: New acne after age 25 in women, or acne persisting through adulthood
Cyclical pattern: Worsening in the week before menstruation (premenstrual flare) corresponding to the luteal phase drop in estrogen and relative androgen dominance
Distribution: Lower face — jawline, chin, and neck — rather than the forehead and nose typical of adolescent comedonal acne
Lesion type: Predominantly deep, inflamed papules and nodules (cystic); fewer surface comedones
Normal circulating androgens: Most women with hormonal acne have testosterone levels within the normal reference range — the issue is follicular sensitivity, not androgen excess

The androgen → sebum → acne pathway

Step 1: Androgen stimulation

Testosterone and its more potent metabolite DHT bind to androgen receptors in sebaceous gland cells (sebocytes). This drives:

Sebocyte proliferation (more cells → larger gland)
Increased sebum synthesis (more lipid production per cell)
Ductal keratinocyte hyperproliferation (narrower follicular opening)

Step 2: IGF-1 amplification

Insulin-like growth factor 1 (IGF-1) — produced by the liver in response to growth hormone and also locally by skin cells — directly stimulates sebum production and promotes the same sebocyte hyperplasia pathway as androgens. This explains:

Why high-glycemic diets worsen acne (insulin → elevated IGF-1)
Why dairy products correlate with acne (dairy contains IGF-1 and bovine growth hormones)
Why pregnancy sometimes improves and sometimes worsens acne (complex hormonal interactions)

Step 3: Comedogenesis and inflammation

Excess sebum + hyperkeratinization of the follicular duct → follicular plugging → Cutibacterium acnes (C. acnes) colonization → inflammatory cytokine release → inflamed papule, pustule, or nodule.

The deep cystic lesions of hormonal acne occur when C. acnes-mediated inflammation penetrates into the surrounding dermis, forming a nodule or pseudocyst.

Pattern recognition: is this hormonal acne?

Strongly suggests hormonal acne:

Adult woman over 25 with new or persistent acne
Jawline and chin distribution
Cyclical premenstrual flares
Deep, painful cystic lesions rather than surface comedones
History of PCOS, irregular periods, or hirsutism
Worsening with progestogen-only contraceptives or at mid-cycle

Check for underlying conditions:

PCOS: Irregular periods, elevated androgens, ovarian cysts, hirsutism → OB/GYN evaluation
Late-onset congenital adrenal hyperplasia (CAH): Elevated 17-hydroxyprogesterone → endocrinology
Androgen-secreting tumors: Sudden, severe androgen excess + other virilizing signs → urgent evaluation (rare)

In most adult women with hormonal acne, circulating androgen levels are normal — the problem is end-organ (follicular) sensitivity, not androgen excess.

Evidence-based treatments

Spironolactone (women only)

Spironolactone is an aldosterone antagonist that also acts as an androgen receptor blocker — it prevents testosterone and DHT from binding sebaceous gland androgen receptors, reducing sebum production at the cellular level.

Dose: 50–200 mg/day; most dermatologists start at 50–100 mg and titrate based on response and side effects.

Evidence: Roberts et al. 2021 (British Journal of Dermatology) — SISTA RCT: spironolactone 100 mg/day vs. placebo in 410 women with persistent acne — significant reduction in lesion count at 24 weeks. The largest RCT for spironolactone in acne to date.

Effect: Takes 2–3 months for full effect; sebum reduction is gradual. Most effective for adult women with hormonal pattern acne; less effective for adolescent or comedonal-predominant acne.

Side effects: Menstrual irregularity (most common — dose-dependent; often resolves), breast tenderness, headache, dizziness. Hyperkalemia risk is low in healthy young women without kidney disease — Plovanich et al. (2015, JAMA Dermatology): routine potassium monitoring is not necessary in women <45 without renal disease. Not for use in men (feminizing effects; gynecomastia).

Contraindication: Pregnancy (teratogenic; requires contraception).

Oral contraceptives (OCPs)

Estrogen-containing OCPs reduce hormonal acne through two mechanisms:

Increased sex hormone-binding globulin (SHBG): Estrogen increases liver production of SHBG → more testosterone bound → less free (active) testosterone
Negative feedback on androgen production: Suppresses LH → reduces ovarian androgen production

FDA-approved OCPs for acne:

Yaz / Yazmin (drospirenone + ethinyl estradiol) — drospirenone has anti-androgenic activity (spironolactone-like)
Estrostep (norethindrone acetate + ethinyl estradiol)
Ortho Tri-Cyclen (norgestimate + ethinyl estradiol)

Progestogen selection matters: Some progestins have androgenic activity and worsen acne. Levonorgestrel and norethindrone (in some formulations) can be androgenic. Anti-androgenic progestins (drospirenone, desogestrel, norgestimate) are preferred.

Timeline: 3–6 months for full effect. Acne may temporarily worsen in months 1–2 as the hormonal axis adjusts.

Combined spironolactone + OCP

For refractory hormonal acne in women, combining spironolactone with an anti-androgenic OCP provides additive benefit: OCP reduces ovarian androgen production and increases SHBG; spironolactone blocks androgen receptors at the follicular level. Both mechanisms operating simultaneously produces greater sebum reduction than either alone.

Low-dose isotretinoin (off-label)

For hormonal acne that is severe, scarring, or unresponsive to topical + hormonal treatment, low-dose isotretinoin (10–20 mg/day or 0.3 mg/kg/day) is used off-label. At low doses:

Sebaceous gland size reduction is maintained
Side effect burden is significantly reduced vs. standard dosing
Monthly monitoring less intensive than standard iPLEDGE protocol (though still required)

Evidence is growing for low-dose continuous isotretinoin for adult women with hormonal acne — particularly useful when hormonal treatment is insufficient.

Topical treatments: what works alongside hormonal therapy

Hormonal treatments address the driver (sebum); topicals address the follicular and inflammatory consequences. Both are needed.

The anti-inflammatory + anti-comedonal stack for hormonal acne:

Adapalene 0.1% (Differin, OTC): Normalizes follicular keratinocyte turnover; reduces comedone formation; anti-inflammatory; works on the structural cause
Benzoyl peroxide 2.5–5%: Kills C. acnes; no resistance; reduces inflammatory lesion count; wash-off or leave-on
Niacinamide 5–10%: Anti-inflammatory; sebum modulation; reduces redness; barrier-supportive during retinoid use
Azelaic acid 15–20%: Dual anti-inflammatory + anti-keratinocyte proliferation; particularly good for hormonal acne with post-acne PIH in darker skin tones

Apply retinoid nightly, benzoyl peroxide AM (not same time — BP oxidizes retinoids). Niacinamide and azelaic acid flexible.

What to avoid

Heavy, occlusive moisturizers and oils on acne-prone areas (particularly the jawline)
Haircare products with oils or silicones that contact the jawline (pompadour-back or up-do can redirect product runoff onto acne-prone skin)
Progestogen-only "mini-pill" OCPs — often androgenic; frequently worsen acne
High-glycemic foods and dairy if there is consistent dietary correlation (individual variation)

Setting expectations

Hormonal acne responds to the right treatment but slowly:

Topical retinoids: 8–12 weeks for meaningful improvement
Spironolactone: 2–3 months for initial response; 4–6 months for full effect
OCPs: 3–6 months for full hormonal axis adjustment
Combination treatment: 6–9 months to reach maximum benefit

Cyclical premenstrual flares may persist early in treatment — this is expected and typically reduces over months of consistent treatment.

Looking for a hormonal acne consultation? Browse dermatology providers on MedSpot →